VR Adviser LLC trimmed its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,629,786 shares of the company's stock after selling 2,925,769 shares during the period. Aquestive Therapeutics comprises about 0.6% of VR Adviser LLC's holdings, making the stock its 25th biggest position. VR Adviser LLC owned about 2.88% of Aquestive Therapeutics worth $9,362,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. New York State Common Retirement Fund lifted its position in shares of Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after acquiring an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at approximately $44,000. Two Sigma Advisers LP acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at approximately $57,000. PKS Advisory Services LLC acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at approximately $63,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at approximately $69,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have recently issued reports on AQST. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Lake Street Capital cut their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $10.67.
Check Out Our Latest Stock Report on AQST
Aquestive Therapeutics Stock Up 2.9%
NASDAQ AQST opened at $2.45 on Tuesday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $5.80. The stock has a market cap of $243.35 million, a price-to-earnings ratio of -5.44 and a beta of 2.02. The business has a fifty day moving average of $2.75 and a 200-day moving average of $3.32.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.
Aquestive Therapeutics Profile
(
Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Further Reading
Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
